Valuation: Ventyx Biosciences, Inc.

Market Cap 644M 572M 534M 487M 918M 62.05B 926M 6.47B 2.51B 31.64B 2.42B 2.37B 102B P/E 2023
-0.75x
P/E 2024 -1.11x
Enterprise Value 402M 357M 333M 304M 573M 38.73B 578M 4.04B 1.57B 19.75B 1.51B 1.48B 63.48B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.78%
Yield 2023 *
-
Yield 2024 -

Last Transcript: Ventyx Biosciences, Inc.

1 day+0.14%
Current year+55.04%
Current year 7.08
Extreme 7.08
25
1 year 3.41
Extreme 3.41
25
3 years 0.78
Extreme 0.783
30.38
5 years 0.78
Extreme 0.783
47.25
10 years 0.78
Extreme 0.783
47.25
Manager TitleAgeSince
President - 2026-03-03
Chief Tech/Sci/R&D Officer - 2024-01-31
Corporate Secretary - 2026-03-03
Director TitleAgeSince
Director/Board Member - 2026-03-03
Director/Board Member - 2026-03-03
Director/Board Member - 2026-03-03
Date Insider Type Main position Quantity % Market Cap. Importance
3/4/26 Issuer sale

Chief Technology Officer

441,000 0.6145%
3/4/26 Issuer sale

Chief Financial Officer

287,013 0.4000%
3/4/26 Issuer sale

Chief Technology Officer

1,806,148 2.5169%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-.--%+288.89%-53.65% 1B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.19%-0.50%+76.26%+110.32% 39.15B
Weighted average by Cap. +0.12%-0.84%+57.55%+137.77%

Financials

2023 2024
Net sales - -
Net income -193M -171M -160M -146M -275M -18.58B -277M -1.94B -751M -9.47B -724M -709M -30.45B -135M -120M -112M -102M -193M -13.01B -194M -1.36B -526M -6.63B -507M -496M -21.32B
Net Debt -240M -213M -199M -181M -342M -23.08B -345M -2.41B -933M -11.77B -900M -880M -37.83B -242M -215M -201M -183M -345M -23.32B -348M -2.43B -943M -11.89B -909M -889M -38.22B
Logo Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Employees
83
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. VTYX Stock